



Company Overview

iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.

The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.

iBio Launches New Sterile Fill-Finish Services

Jun 3 2019, 8:00 AM EDT

iBio Announces Appointment of Thomas F. Isett to Board of Directors

Apr 1 2019, 8:30 AM EDT

iBio Provides Status Update on its Continuing Litigation Against Fraunhofer

Dec 14 2018, 8:00 AM EST

Stock Overview

| | |
|------------|----------------------|
| Symbol | IBIO |
| Exchange | NYSE American |
| Market Cap | 16.35m |
| Last Price | \$0.83 |
| 52-Week | \$0.495021 - \$1.215 |

06/17/2019 04:10 PM EDT

Investor Relations

iBio, Inc.
T: 302-355-9452
ir@ibioinc.com

Management Team

Robert B. Kay

Executive Chairman and Chief Executive Officer

Robert L. Erwin

President

R. Barry Holtz, Ph.D.

President, iBio CDMO

James P. Mullaney

Chief Financial Officer

Terence E. Ryan, Ph.D.

Chief Scientific Officer

James Abbey, Ph.D.

Vice President of Strategic Business Development

Wayne P. Fitzmaurice, Ph.D.

Vice President, Intellectual Property

iBio Inc.

600 Madison Avenue
Suite 1601
New York, NY 10022

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.